← Eichor
Condition: Locally Advanced Unresectable Esophageal Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Locally Advanced Unresectable Esophageal Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
Phase 2 · 8 location(s) · Ming-Yu Lien · NCT07039162Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06452602Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Pos
Phase 2 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT06885814Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenoca
Phase 2 · 2 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07102901A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
Phase 1/Phase 2 · 22 location(s) · Merck Sharp & Dohme LLC · NCT07405151Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unres
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07086469Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · Sichuan University · NCT06675201Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First
Phase 1/Phase 2 · 51 location(s) · Merck Sharp & Dohme LLC · NCT06469944Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer
Phase 3 · 1 location(s) · Qinghai Red Cross Hospital · NCT06338683A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastati
Phase 2 · 6 location(s) · BeOne Medicines · NCT07554521A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Phase 1/Phase 2 · 14 location(s) · Astellas Pharma Global Development, Inc. · NCT07488676Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer
Phase 3 · 1 location(s) · Sunshine Lake Pharma Co., Ltd. · NCT04415853Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Ad
Phase 2 · 1 location(s) · Ning Jiang, M.D./Ph.D. · NCT07530094Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
Phase 2 · 7 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07733830Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC
Phase 2 · 1 location(s) · Sichuan University · NCT07519486Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC
Phase 2 · 1 location(s) · Sichuan University · NCT06603402Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squa
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06912074Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access an
Phase 2 · 1 location(s) · Mayo Clinic · NCT06265285Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
Phase 1/Phase 2 · 1 location(s) · Shanghai Chest Hospital · NCT06173986Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06988956Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophagea
Phase 2 · 1 location(s) · Second Affiliated Hospital of Zunyi Medical University · NCT07559045Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Loc
Phase 1/Phase 2 · 18 location(s) · Aulos Bioscience, Inc. · NCT05267626Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06410651A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants W
Phase 1/Phase 2 · 32 location(s) · Marengo Therapeutics, Inc. · NCT05592626A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizuma
Phase 2/Phase 3 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07554456Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Phase 1/Phase 2 · 44 location(s) · Merck Sharp & Dohme LLC · NCT06780111Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
Phase 2 · 1 location(s) · Fujian Medical University Union Hospital · NCT06510660Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophagea
Phase 2 · 1 location(s) · Jiangsu Cancer Institute & Hospital · NCT07435454A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally
Phase 2 · 1 location(s) · Shanghai Chest Hospital · NCT06709417Oncolytic Virus in Esophageal Squamous Cell Carcinoma
Phase 1/Phase 2 · 1 location(s) · Sichuan University · NCT07061704
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.